New U.S. FDA Warning for Weight Loss Drugs Ozempic and Wegovy

Medical News: U.S. FDA Adds New Safety Label for Weight Loss Medications
The U.S. Food and Drug Administration (FDA) has recently updated the safety labels on popular weight loss medications like Ozempic and Wegovy, highlighting a new warning for patients using these drugs. The warning addresses the risk of a condition known as pulmonary aspiration, which can occur during procedures involving general anesthesia. Pulmonary aspiration takes place when food or liquid unintentionally enters the lungs, potentially leading to severe complications like lung infections, inflammation, and even death.


 New U.S. FDA Warning for Weight Loss Drugs Ozempic and Wegovy

This Medical News report underscores why such a warning is necessary for patients on GLP-1 receptor agonists, a class of medications that includes not only Ozempic and Wegovy but also drugs like Saxenda, Victoza, and Mounjaro. These drugs are commonly used for weight loss and diabetes management, working by slowing down digestion, which helps users feel fuller for longer. This characteristic, while beneficial for controlling appetite and managing blood sugar, becomes a concern during procedures requiring sedation, as a full stomach increases the risk of aspiration under anesthesia.
 
Understanding Pulmonary Aspiration Risks
Pulmonary aspiration is particularly hazardous under general anesthesia or deep sedation because the body’s natural defenses, such as the cough reflex, are weakened, and a person cannot actively clear their lungs. The U.S. FDA's updated label is a proactive measure to ensure that patients and healthcare providers are aware of this risk, especially given recent cases where individuals undergoing surgery while on these drugs faced complications. In some instances, patients reportedly followed the usual fasting guidelines - refraining from eating for six to eight hours before surgery - yet still had stomach contents that increased their risk of aspiration.
 
The U.S. FDA’s warning is directed at those on GLP-1 drugs who might not realize the implications of a slower digestive process when undergoing surgery. By slowing the stomach’s emptying rate, GLP-1 medications, like semaglutide (the active ingredient in Ozempic and Wegovy) and liraglutide (used in Saxenda and Victoza), leave residual stomach contents even after extended fasting. This delay in digestion can lead to unexpected complications when anesthesia is involved, posing a greater risk for those who are unaware of this side effect.
 
Which Drugs Are Affected?
The U.S. FDA’s updated warning applies to several GLP-1 receptor agonist medications. These include:
 
Ozempic, Rybelsus, and Wegovy (all contain semaglutide)
Saxenda and Victoza (both contain liraglutide)
Mounjaro and Zepbound (both contain tirzepatide)
 
These drugs, widely prescribed for both weight management and diabetes, have proven effective in helping users achieve their health goals. However, with the recent findings, medical professionals and patients n eed to exercise caution if a medical procedure requiring anesthesia is planned.
 
Pre-Surgery Guidelines and Safety Tips
In response to the FDA’s new warning, the American Society of Anesthesiologists (ASA) has established updated guidelines to help reduce the risk of aspiration among GLP-1 drug users. The ASA advises patients on these medications to switch to a 24-hour liquid-only diet before any surgery. For patients at high risk of aspiration, doctors may also perform an ultrasound to check for stomach contents before anesthesia is administered.
 
Some healthcare providers are now recommending an even more cautious approach, suggesting that patients stop GLP-1 medications a week prior to any procedure involving sedation. According to these providers, food remnants have occasionally been found in patients’ stomachs during surgeries even after they had fasted, highlighting the importance of thorough preparation.
 
Dr. Angela Fitch, a co-founder of a weight-inclusive clinic, explained that most patients on GLP-1 drugs will likely experience no issues during surgery. However, because these drugs slow stomach emptying, it’s crucial to take precautions. Rather than stopping medication entirely, Fitch advises a longer fasting period to ensure the stomach is empty by the time anesthesia is administered.
 
Rising Popularity of GLP-1 Drugs Like Ozempic and Wegovy
GLP-1 receptor agonists have surged in popularity as weight loss tools, particularly since Wegovy’s approval by the U.S. FDA in 2021. Known for aiding in weight management, these drugs are increasingly used by patients across the United States. A survey conducted in May 2024 by KFF Health News revealed that around 12% of adults in the U.S. have tried a GLP-1 drug, either for weight loss or for diabetes management.
https://www.kff.org/health-costs/poll-finding/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/
 
The newfound awareness around pulmonary aspiration risks highlights the importance of patient education. While the majority of GLP-1 users won’t encounter this complication, the U.S. FDA’s updated label aims to alert individuals to the rare but serious risks associated with these medications in specific situations. Patients taking these drugs are encouraged to inform their doctors if they anticipate any procedures requiring sedation.
 
Why Is This Warning Coming Now?
Although the aspiration risk linked to GLP-1 drugs has been acknowledged within the medical community for years, recent developments, including the European Medicines Agency’s similar advisory, have spurred renewed attention. The European agency released its guidelines this summer, recommending that patients consult with healthcare providers before undergoing anesthesia.
https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-july-2024#:~:text=As%20part%20of%20their%20action,sedation%20when%20taking%20these%20medicines.
 
While research has not proven a direct connection between GLP-1 drugs and increased aspiration risk, these guidelines reflect a precautionary stance, given the potential for delayed stomach emptying associated with these drugs.
 
With the U.S. FDA’s recent warning, medical providers in the U.S. are likely to be more vigilant when preparing patients on GLP-1 medications for surgery.
https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=2711
 
Fitch emphasized that more research is essential to fully understand how GLP-1 drugs might impact patients facing surgery. She believes the FDA’s updated warning will not only safeguard patients but also raise awareness among those who may not know about the potential risks.
 
Conclusion
The FDA’s new warning on GLP-1 drugs, including Ozempic and Wegovy, aims to inform patients and healthcare professionals about the potential risk of pulmonary aspiration during anesthesia. This precaution is especially relevant as these medications continue to gain popularity for weight loss and diabetes management. Patients should take note of the new recommendations for fasting and consult their doctors about any planned procedures involving sedation. By increasing awareness, the FDA hopes to reduce the likelihood of complications during surgeries and ensure patient safety. For individuals on GLP-1 medications, it’s essential to disclose their use to healthcare providers when undergoing any procedure requiring anesthesia to mitigate risks effectively.
 
For the latest Med or Drug News, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/weight-loss-drugs-like-wegovy-and-ozempic-can-drive-suicidal-ideation-in-some
 
https://www.thailandmedical.news/news/move-over-ozempic-and-wegovy-fermented-blackberries-the-new-anti-obesity-and-weight-loss-remedy